Study:
Phase III Study of Adriamycin/Taxotere Versus Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known which combination chemotherapy regimen is more effective for breast cancer.
Purpose:
Randomized phase III trial to compare the effectiveness of two combination
chemotherapy regimens in treating women with breast cancer who have undergone surgery to
remove the tumor.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Breast Cancer |
Drug: cyclophosphamide
Drug: docetaxel
Drug: doxorubicin hydrochloride |
Phase 3 |
Verified by
Eastern Cooperative Oncology Group
January, 2010
Sponsored by: Eastern Cooperative Oncology Group
Information provided by: Eastern Cooperative Oncology Group
ClinicalTrials.gov identifier: NCT00003519
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States
Lori J. Goldstein, MD., Study Chair
Silvana Martino, DO., Study Chair
Edith A. Perez, MD., Study Chair
Larry Norton, MD., Study Chair